کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
10738965 | 1046849 | 2005 | 8 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Inhibition of brain damage by edaravone, a free radical scavenger, can be monitored by plasma biomarkers that detect oxidative and astrocyte damage in patients with acute cerebral infarction
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
mAbInversion-recoveryNIH stroke scaleflow-sensitive alternating inversion recoveryoxLDLPWINIHSSDWI8-OHdG8-hydroxydeoxyguanosine - 8 هیدروکسی دیواکسی گوآزینMonoclonal antibody - آنتی بادی مونوکلونالFLAIR - اشتباهmiddle cerebral artery occlusion/reperfusion - انسداد / عود مجدد شریان مغزی میانیAcute cerebral infarction - انفارکتوس حاد مغزیPlasma biomarker - بیومارکرر پلاسماFree radical scavenger - تسخیر کننده رادیکال آزادPerfusion-weighted imaging - تصویربرداری با وزن متعادلdiffusion-weighted imaging - تصویربرداری با وضوح تصویربرداریFree radicals - رادیکال آزادSOD - سدSuperoxide dismutase - سوکسوکس دیسموتازOxidized low-density lipoprotein - لیپوپروتئین با چگالی کم اکسید شده
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
سالمندی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Inhibition of brain damage by edaravone, a free radical scavenger, can be monitored by plasma biomarkers that detect oxidative and astrocyte damage in patients with acute cerebral infarction Inhibition of brain damage by edaravone, a free radical scavenger, can be monitored by plasma biomarkers that detect oxidative and astrocyte damage in patients with acute cerebral infarction](/preview/png/10738965.png)
چکیده انگلیسی
We assess the availability of plasma biomarkers to monitor the brain damage and the therapeutic efficacy of edaravone. The study consisted of 51 patients with ischemic cerebral infarcts. They were divided into 2 groups: GI (n = 24) had cortical lesions, and GII (n = 27) had lesions in the basal ganglia or brain stem. Edaravone was administered to 27 randomly selected patients (GIa, n = 13; GIIa, n = 14) and its efficacy was studied by comparing their plasma OxLDL, S-100B, and MnSOD levels to those in patients without edaravone (GIb, n = 11, GIIb, n = 13). Three days after the start of edaravone, plasma OxLDL was significantly lower in GIa than GIb patients (0.177 ± 0.024 ng/μg apoB vs 0.219 ± 0.026, P < 0.05). In GIIa patients, pre- and posttreatment plasma OxLDL was not significantly different (0.156 ± 0.013 vs 0.152 ± 0.020). In GIa patients, S-100B and MnSOD were significantly lower than in GIb patients (P < 0.05). The neurological condition at the time of discharge had recovered in GIa but not GIb patients. Ours is the first evidence to confirm the efficacy of edaravone by plasma biomarkers. In patients with cortical infarcts, edaravone reduced oxidative damage, thereby limiting the degree of brain damage.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Free Radical Biology and Medicine - Volume 39, Issue 8, 15 October 2005, Pages 1109-1116
Journal: Free Radical Biology and Medicine - Volume 39, Issue 8, 15 October 2005, Pages 1109-1116
نویسندگان
Masaaki Uno, Keiko T. Kitazato, Atsuhiko Suzue, Kazuhito Matsuzaki, Masahumi Harada, Hiroyuki Itabe, Shinji Nagahiro,